However, the findings of this study may help identify the optimal patient population of EGFR exon 21 L858R point mutation-positive NSCLC patients who would benefit from EGFR-TKI therapy, in turn improving the prognosis of patients with NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.